Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Show other versions (1)

Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain une...

Full description

Bibliographic Details
Main Authors: Claas, Allison Mary, Atta, Lyla H., Gordonov, Simon, Meyer, Aaron Samuel, Lauffenburger, Douglas A
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Language:English
Published: Springer US 2018
Online Access:http://hdl.handle.net/1721.1/117218
https://orcid.org/0000-0003-1224-8153
https://orcid.org/0000-0001-6284-2711
https://orcid.org/0000-0002-0050-989X

Internet

http://hdl.handle.net/1721.1/117218
https://orcid.org/0000-0003-1224-8153
https://orcid.org/0000-0001-6284-2711
https://orcid.org/0000-0002-0050-989X

Similar Items